Accelerating Costs And Funding Risk Will Undermine Biotech Stability
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 11 Analysts
Published
27 Jul 25
Updated
27 Jul 25
AnalystLowTarget's Fair Value
US$297.34
46.1% overvalued intrinsic discount27 Jul
US$434.35
1Y
12.3%7D
2.7%